|
Outcome of BRCA 1/2-Mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V). |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline (I) |
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - Infinity Pharmaceuticals |
Research Funding - Abbvie; Bristol-Myers Squibb; Infinity Pharmaceuticals; Millennium; Novartis; Saladax Biomedical; Spectrum Pharmaceuticals; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
Hussein Abdul-Hassan Tawbi |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Amgen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie; Abbvie (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |